Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.

Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA.

Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738. [Epub ahead of print]

PMID:
29992557
2.
3.

Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.

Kurbacher CM, Horn O, Kurbacher JA, Herz S, Kurbacher AT, Hildenbrand R, Bollmann R.

Oncologist. 2015 Nov;20(11):1333-41. doi: 10.1634/theoncologist.2015-0076. Epub 2015 Sep 28.

4.

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis.

Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz HJ, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens CC, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW.

Oncol Res Treat. 2015;38(5):221-9. doi: 10.1159/000381631. Epub 2015 May 4.

5.

Isolation and culture of ovarian cancer cells and cell lines.

Kurbacher CM, Korn C, Dexel S, Schween U, Kurbacher JA, Reichelt R, Arenz PN.

Methods Mol Biol. 2011;731:161-80. doi: 10.1007/978-1-61779-080-5_15.

PMID:
21516407
6.

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.

Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, Dexel S, Reinhold U, Cree IA.

BMC Cancer. 2009 Jan 28;9:38. doi: 10.1186/1471-2407-9-38.

7.

A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.

Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S; TCA Ovarian Cancer Trial Group.

Anticancer Drugs. 2007 Oct;18(9):1093-101.

PMID:
17704660
8.

Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.

Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfützner A, Kurbacher CM, Schöndorf T, Breidenbach M.

Anticancer Drugs. 2006 Oct;17(9):1041-4.

PMID:
17001177
9.

Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.

Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA.

Anticancer Drugs. 2005 Oct;16(9):969-76.

PMID:
16162973
10.

Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.

Kurbacher CM, Kurbacher JA, Cramer EM, Rhiem K, Mallman PK, Reichelt R, Reinhold U, Stier U, Cree IA.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):23-6.

11.

Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.

Kurbacher CM, Cree IA.

Methods Mol Med. 2005;110:101-20. Review.

PMID:
15901931
12.

Treosulfan and gemcitabine.

Cree IA, Neale MH, Reinhold U, Kurbacher CM.

J Cancer Res Clin Oncol. 2005 May;131(5):329-30; author reply 331. Epub 2005 Feb 8. No abstract available.

PMID:
15700153
13.

Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells.

Schöndorf T, Hoopmann M, Breidenbach M, Rein DT, Göhring UJ, Becker M, Mallmann P, Kurbacher CM.

Anticancer Drugs. 2004 Mar;15(3):265-8.

PMID:
15014360
14.

Preeclamptic women are deficient of interleukin-10 as assessed by cytokine release of trophoblast cells in vitro.

Rein DT, Breidenbach M, Hönscheid B, Friebe-Hoffmann U, Engel H, Göhring UJ, Uekermann L, Kurbacher CM, Schöndorf T.

Cytokine. 2003 Aug 21-Sep 7;23(4-5):119-25.

PMID:
12967647
15.

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA.

BMC Cancer. 2003 Jul 3;3:19.

16.

Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer.

Breidenbach M, Rein DT, Schöndorf T, Schmidt T, König E, Valter M, Kurbacher CM.

Anticancer Drugs. 2003 Jun;14(5):341-6.

PMID:
12782939
17.

ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.

Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janát MM, Untch M, Konecny G, Bruckner HW, Cree IA.

Recent Results Cancer Res. 2003;161:221-30. Review.

PMID:
12528810
18.

Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.

Schöndorf T, Neumann R, Benz C, Becker M, Riffelmann M, Göhring UJ, Sartorius J, von König CH, Breidenbach M, Valter MM, Hoopmann M, Di Nicolantonio F, Kurbacher CM.

Recent Results Cancer Res. 2003;161:111-6.

PMID:
12528803
19.

Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.

Rein DT, Kurbacher CM, Breidenbach M, Schöndorf T, Schmidt T, König E, Göhring UJ, Blohmer JU, Mallmann P.

Gynecol Oncol. 2002 Oct;87(1):98-103.

PMID:
12468349
20.

Chemosensitivity of normal human trophoblasts evaluated by a newly developed ATP-based luminescence assay.

Kurbacher CM, Kurbacher JA, Cree IA, Wardelmann E, Stier U, Kolhagen H, Scharl A, Andreotti PE.

Anticancer Drugs. 2002 Aug;13(7):701-8.

PMID:
12187326
21.

Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines.

Schöndorf T, Kurbacher CM, Göhring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P, Neumann R.

Anticancer Res. 2002 Jul-Aug;22(4):2199-203.

PMID:
12174904
22.

Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.

Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA.

Anticancer Drugs. 2002 Jul;13(6):625-30.

PMID:
12172508
23.

Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.

Breidenbach M, Rein DT, Mallmann P, Kurbacher CM.

Anticancer Drugs. 2002 Feb;13(2):173-6.

PMID:
11901311
24.

Cytokine expression in peripheral blood lymphocytes indicates a switch to T(HELPER) cells in patients with preeclampsia.

Rein DT, Schondorf T, Gohring UJ, Kurbacher CM, Pinto I, Breidenbach M, Mallmann P, Kolhagen H, Engel H.

J Reprod Immunol. 2002 Mar;54(1-2):133-42.

PMID:
11839400
25.

Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma.

Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, Kurbacher CM, Hall P, Corrie PG, Cree IA.

Melanoma Res. 2001 Dec;11(6):601-9.

PMID:
11725206
26.

Interaction of cisplatin, paclitaxel and adriamycin with the tumor suppressor PTEN.

Schöndorf T, Becker M, Göhring UJ, Wappenschmidt B, Kolhagen H, Kurbacher CM.

Anticancer Drugs. 2001 Nov;12(10):797-800.

PMID:
11707646
27.

The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects.

Rein DT, Kurbacher CM.

Anticancer Drugs. 2001 Nov;12(10):787-95. Review.

PMID:
11707645
28.

Heterogeneity of proteinkinase C activity and PKC-zeta expression in clinical breast carcinomas.

Schöndorf T, Kurbacher CM, Becker M, Warm M, Kolhagen H, Göhring UJ.

Clin Exp Med. 2001 Mar;1(1):1-8.

PMID:
11467396
29.

Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy.

Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallmann P, Römer T.

Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):168-73.

PMID:
11451543
31.

Ex vivo assays to evaluate the role of protein kinase C in tumor cells of patients with breast cancer.

Schöndorf T, Becker M, Kolhagen H, Kurbacher CM, Göhring UJ.

Anticancer Res. 2000 Nov-Dec;20(6D):5073-6.

PMID:
11326671
32.

Lack of correlation between P53 expression, BCL-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer.

Rein DT, Schöndorf T, Breidenbach M, Janát MM, Weikelt A, Göhring UJ, Becker M, Mallmann P, Kurbacher CM.

Anticancer Res. 2000 Nov-Dec;20(6D):5069-72.

PMID:
11326670
33.

The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.

Neale MH, Lamont A, Hindley A, Kurbacher CM, Cree IA.

Anticancer Drugs. 2000 Nov;11(10):865-71.

PMID:
11142695
34.
35.

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

Schwonzen M, Kurbacher CM, Mallmann P.

Anticancer Drugs. 2000 Oct;11(9):681-5.

PMID:
11129728
36.

Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.

Breidenbach M, Rein D, Schmidt T, Heindel W, Kolhagen H, Mallmann P, Kurbacher CM.

Anticancer Drugs. 2000 Apr;11(4):269-73.

PMID:
10898542
37.

Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas.

Schöndorf T, Scharl A, Kurbacher CM, Bien O, Becker M, Neumann R, Kolhagen H, Rustemeyer J, Mallmann P, Göhring UJ.

Cancer Lett. 1999 Nov 15;146(2):195-9.

PMID:
10656626
38.

Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.

Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE.

Anticancer Drugs. 1999 Jun;10(5):437-44.

PMID:
10477162
39.

ATP-based tumor chemosensitivity testing: assisting new agent development.

Cree IA, Kurbacher CM.

Anticancer Drugs. 1999 Jun;10(5):431-5. Review.

PMID:
10477161
40.

Fetal cord blood as an alternative source of hematopoietic progenitor cells: immunophenotype, maternal cell contamination, and ex vivo expansion.

Engel H, Kaya E, Bald R, Kolhagen H, Grecu O, Schöndorf T, Brenne U, Kurbacher CM, Göhring UJ, Kleine M, Mallmann P.

J Hematother. 1999 Apr;8(2):141-55.

PMID:
10349908
41.

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.

Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN.

Br J Cancer. 1999 Mar;79(9-10):1487-93.

42.

Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.

Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.

Clin Cancer Res. 1997 Sep;3(9):1527-33.

43.

Detection of chromosomal aberrations in tumor cells and tumor infiltrating lymphocytes by molecular cytogenetics in patients with gynecological cancer.

Engel H, Friedrich J, Kleespies C, Kurbacher CM, Schöndorf T, Grecu O, Kolhagen H, Mallmann P.

Cancer Genet Cytogenet. 1998 Oct 15;106(2):159-65.

PMID:
9797783
44.

Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).

Kurbacher CM, Mallmann PK.

Anticancer Res. 1998 May-Jun;18(3C):2203-10. Review.

PMID:
9703784
45.

Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.

Schöndorf T, Engel H, Kurbacher CM, Brenne U, Kolhagen H, Göhring UJ, Scharl A, Mallmann P.

J Soc Gynecol Investig. 1998 Mar-Apr;5(2):102-7.

PMID:
9509389
46.

Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.

Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Müller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE.

Anticancer Drugs. 1998 Jan;9(1):51-7.

PMID:
9491792
47.

The ex vivo chemosensitivity profile of choroidal melanoma.

Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN.

Anticancer Drugs. 1997 Sep;8(8):756-62.

PMID:
9396619
48.

Individualizing chemotherapy for solid tumors--is there any alternative?

Cree IA, Kurbacher CM.

Anticancer Drugs. 1997 Jul;8(6):541-8. Review.

PMID:
9300568
49.

Tumor chemosensitivity and chemoresistance assays.

Cree IA, Petty RD, Kurbacher CM, Untch M.

Cancer. 1996 Nov 1;78(9):2031-2. No abstract available.

PMID:
8909327
50.

Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity.

Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE, Bruckner HW.

Anticancer Drugs. 1996 Aug;7(6):630-5.

PMID:
8913430

Supplemental Content

Loading ...
Support Center